Bartosz Puła

ABSTRACT Introduction Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. Although treatment has shifted from immunochemotherapy to novel targeted drugs over the last ten years, novel therapies remain under investigation, particularly in relapsed and refractory patients. Areas covered This review describes the use of approved targeted drugs and novel therapies in treatment-naïve and relapsed or refractory CLL.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview by Kamil Wiśniewski Kamil Wiśniewski Scilit Preprints.org Google Scholar * and Bartosz Puła Bartosz Puła Scilit Preprints.org Google Scholar Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland * Author to whom correspondence should be addressed. Int. J. Mol. Sci.